Drug Search Results
More Filters [+]

Ricolinostat

Alternative Names: ricolinostat, acy-1215
Latest Update: 2024-04-15
Latest Update Note: PubMed Publication

Product Description

Ricolinostat is an orally bioavailable, specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity. Ricolinostat selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation. This leads to an accumulation of unfolded and misfolded ubiquitinated proteins and may eventually induce cancer cell apoptosis, and inhibition of cancer cell growth. HDAC6, a class II HDAC deacetylase located in the cytoplasm, appears to play a key role in the formation and activation of the aggresomes needed for degradation of misfolded proteins. Compared to non-selective HDAC inhibitor, ACY-1215 is able to reduce the toxic effects on normal, healthy cells. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Ricolinostat)

Mechanisms of Action: HDAC6 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ricolinostat

Countries in Clinic: China, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 2: Peripheral Nervous System Diseases

Phase 1: Chemotherapy-induced Peripheral Neuropathy|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Multiple Myeloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT02787369

P1

Active, not recruiting

Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia

2024-04-01

BCRG-CN-101

P1

Completed

Peripheral Nervous System Diseases

2023-11-10

REGY-DN-201

P2

Completed

Peripheral Nervous System Diseases

2022-10-31

BCRG-CN-102

P1

Completed

Peripheral Nervous System Diseases

2022-01-30

Recent News Events